Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263–275) epitope: an MHC anchor variant peptide for immune modulation
2007

Identifying a New Peptide for Rheumatoid Arthritis Treatment

publication Evidence: moderate

Author Information

Author(s): Annemieke MH Boots, Henk Hubers, Milou Kouwijzer, Leontien den Hoed-van Zandbrink, Bernice M Westrek-Esselink, Cindy van Doorn, Rachel Stenger, Ebo S Bos, Marie-jose C van Lierop, Gijs F Verheijden, Cornelis M Timmers, Catharina J van Staveren

Primary Institution: NV Organon, Research Laboratories, Oss, The Netherlands

Hypothesis

Can an altered peptide ligand based on the HC gp-39 epitope modulate T cell responses in rheumatoid arthritis?

Conclusion

The study identified a non-classical altered peptide ligand that may help in treating rheumatoid arthritis by modulating the immune response.

Supporting Evidence

  • The study identified key residues in the HC gp-39 epitope that are important for T cell recognition.
  • Altered peptide ligands were developed that showed potential to modulate immune responses in animal models.
  • Findings suggest that the identified peptide could be beneficial for rheumatoid arthritis immunotherapy.

Takeaway

Researchers found a new peptide that might help treat rheumatoid arthritis by changing how the immune system reacts to a specific protein in the body.

Methodology

The study used T cell hybridomas from HLA-DR4 transgenic mice to identify key residues in the HC gp-39 epitope and tested modified peptides for their ability to modulate T cell responses.

Limitations

The study primarily focused on in vitro and animal models, which may not fully translate to human responses.

Digital Object Identifier (DOI)

10.1186/ar2269

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication